Evidence map›Paper›PMID 38177097›Full record

ArticleCell death discovery2024

Targeting K

Luca Matteo Todesca, Matthias Gerke, Emma Etmar Bulk, Magdalena Bachmann, Alisa Rudersdorf, Lorenzo Antonuzzo, Serena Pillozzi, Martina Düfer, Ildiko Szabo, Albrecht Schwab

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell death discovery, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.9field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Luca Matteo TodescaInstitute of Physiology II, University of Münster, Münster, Germany. l.m.todesca@gmail.com.ORCID http://orcid.org/0000-0002-3266-9038
Matthias GerkeInstitute of Physiology II, University of Münster, Münster, Germany.
Emma Etmar BulkInstitute of Physiology II, University of Münster, Münster, Germany.
Magdalena BachmannDepartment of Biology, University of Padova, Padua, Italy.
Alisa RudersdorfInstitute of Pharmaceutical and Medicinal Chemistry, University of Münster, Münster, Germany.
Lorenzo AntonuzzoDepartment of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Serena PillozziDepartment of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Martina DüferInstitute of Pharmaceutical and Medicinal Chemistry, University of Münster, Münster, Germany.
Ildiko SzaboDepartment of Biology, University of Padova, Padua, Italy.ORCID http://orcid.org/0000-0002-3637-3947
Albrecht SchwabInstitute of Physiology II, University of Münster, Münster, Germany.
University of Münster · DEUniversity of Florence · ITUniversity of Padua · IT

Funding

Deutsche Forschungsgemeinschaft (German Research Foundation) GRK 2515/1
6 · The paper itself

Abstract

Almost all non-small cell lung cancer (NSCLC) patients initially responding to EGFR tyrosine kinase inhibitors (TKIs) develop acquired resistance. Since K

Identifiers

PMID38177097
PMCPMC10767088
OpenAlexW4390588647

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.